Clinical Trial Update: An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma [Phase 2]

View source ↗

Summary

An open-label Phase II trial updates results for nivolumab alone or in combination with ipilimumab in adults with progressive or recurrent meningioma. Results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningioma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Meningiomas | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-26